Welcome to the international HTA database

Showing [16861 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Setmelanotide (new therapeutic indication: obesity and control of hunger, Bardet-Biedl syndrome, ≥ 6 years)]
2023	National Institute for Health and Care Excellence (NICE)	Somatrogon for treating growth disturbance in children and young people aged 3 years and over. NICE technology appraisal guidance 863
2023	Agency for Healthcare Research and Quality (AHRQ)	Nonemergent percutaneous coronary intervention versus optimal medical treatment for stable ischemic heart disease: a rapid response literature review
2023	National Institute for Health and Care Excellence (NICE)	Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted. NICE technology appraisal guidance 864
2023	National Institute for Health and Care Excellence (NICE)	Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. NICE technology appraisal guidance 865
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Antibiotic products for treatment of trauma-related osteomyelitis
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Talquetamab (multiple myeloma, at least 3 prior therapies)]
2023	National Institute for Health and Care Excellence (NICE)	Regorafenib for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 866
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after the deadline: B-cell acute lymphoblastic leukaemia (ALL), relapsed/ refractory, 0 ≤ 25 years)]
2023	National Institute for Health and Care Excellence (NICE)	Mitapivat for treating pyruvate kinase deficiency (terminated appraisal). NICE technology appraisal guidance 867
2023	NIHR Health Technology Assessment programme	Clinical and cost effectiveness of endoscopic bipolar radiofrequency ablation for the treatment of malignant biliary obstruction: a systematic review
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after the deadline (diffuse large B-cell lymphoma, (DLBCL))]
2023	National Institute for Health and Care Excellence (NICE)	Vutrisiran for treating hereditary transthyretin-related amyloidosis. NICE technology appraisal guidance 868
2023	The Danish Health Technology Council (DHTC)	[Assessment of pocket-sized handheld ultrasound devices for point-of-care examination of patients in emergency departments]
2023	Agency for Healthcare Research and Quality (AHRQ)	Nutrition as prevention for improved cancer health outcomes
2023	Health Information and Quality Authority (HIQA)	18F-PSMA PET/CT in the staging of primary prostate cancer and the restaging of recurrent prostate cancer: evidence synthesis to support a generic justification decision
2023	National Institute for Health and Care Excellence (NICE)	Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal). NICE technology appraisal guidance 869
2023	National Institute for Health and Care Excellence (NICE)	Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. NICE technology appraisal guidance 870
2023	Agency for Healthcare Research and Quality (AHRQ)	Partial breast irradiation for breast cancer
2023	National Institute for Health and Care Excellence (NICE)	Eptinezumab for preventing migraine. NICE technology appraisal guidance 871
2023	National Institute for Health and Care Excellence (NICE)	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 872
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines and clinical pathways for management of acute lower GI bleeding
2023	National Institute for Health and Care Excellence (NICE)	Cannabidiol for treating seizures caused by tuberous sclerosis complex. NICE technology appraisal guidance 873
2023	Agency for Healthcare Research and Quality (AHRQ)	Pharmacologic and nonpharmacologic treatments for posttraumatic stress disorder: an update of the PTSD repository evidence base
2023	National Institute for Health and Care Excellence (NICE)	Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. NICE technology appraisal guidance 874
2023	NIHR Health Technology Assessment programme	Adjunctive medication management and contingency management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT
2023	National Institute for Health and Care Excellence (NICE)	Semaglutide for managing overweight and obesity. NICE technology appraisal guidance 875
2023	National Institute for Health and Care Excellence (NICE)	Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer. NICE technology appraisal guidance 876
2023	Agency for Healthcare Research and Quality (AHRQ)	Postpartum care up to 1 year after pregnancy: a systematic review and meta-analysis
2023	National Institute for Health and Care Excellence (NICE)	Finerenone for treating chronic kidney disease in type 2 diabetes. NICE technology appraisal guidance 877
2023	National Institute for Health and Care Excellence (NICE)	Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. NICE technology appraisal guidance 878
2023	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal). NICE technology appraisal guidance 879
2023	Ontario Health	Bariatric surgery for adults with class I obesity and difficult-to-manage type 2 diabetes
2023	National Institute for Health and Care Excellence (NICE)	Tezepelumab for treating severe asthma. NICE technology appraisal guidance 880
2023	NIHR Health Technology Assessment programme	Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT RCT with embedded process and economic evaluation
2023	National Institute for Health and Care Excellence (NICE)	Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments. NICE technology appraisal guidance 881
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Perinatal and infant mental health care in Austria. A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol
2023	NIHR Health Technology Assessment programme	Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study
2023	National Institute for Health and Care Excellence (NICE)	Voclosporin with mycophenolate mofetil for treating lupus nephritis. NICE technology appraisal guidance 882
2023	National Institute for Health and Care Excellence (NICE)	Middle meningeal artery embolisation for chronic subdural haematomas. NICE interventional procedures guidance 779
2023	Agency for Healthcare Research and Quality (AHRQ)	Radiation therapy for metastatic bone disease: effectiveness and harms
2023	NIHR Health Technology Assessment programme	Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023	National Institute for Health and Care Excellence (NICE)	Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 883
2023	National Institute for Health and Care Excellence (NICE)	Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. NICE interventional procedures guidance 778
2023	NIHR Health Technology Assessment programme	Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT
2023	National Institute for Health and Care Excellence (NICE)	Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal). NICE technology appraisal guidance 884
2023	National Institute for Health and Care Excellence (NICE)	Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. NICE interventional procedures guidance 777
2023	NIHR Health and Social Care Delivery Program	Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT
2023	National Institute for Health and Care Excellence (NICE)	Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 885
2023	National Institute for Health and Care Excellence (NICE)	Biodegradable subacromial spacer insertion for rotator cuff tears. NICE interventional procedures guidance 775
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patient/social, ethical and legal elements
2023	NIHR Health Technology Assessment programme	Posterior cervical foraminotomy versus anterior cervical discectomy for cervical brachialgia: the FORVAD RCT
2023	National Institute for Health and Care Excellence (NICE)	Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy. NICE technology appraisal guidance 886
2023	National Institute for Health and Care Excellence (NICE)	Extracorporeal carbon dioxide removal for acute respiratory failure. NICE interventional procedures guidance 776
2023	NIHR Health and Social Care Delivery Program	Mental health crisis care for children and young people aged 5 to 25 years: the CAMH-Crisis evidence synthesis
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Urine pregnancy screening for patients with and without the capacity for pregnancy
2023	NIHR Health Technology Assessment programme	Exercise therapy for tendinopathy: a mixed-methods evidence synthesis exploring feasibility, acceptability and effectiveness
2023	National Institute for Health and Care Excellence (NICE)	Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 887
2023	National Institute for Health and Care Excellence (NICE)	Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. NICE interventional procedures guidance 774
2023	Health Information and Quality Authority (HIQA)	International review of the epidemiology of long COVID
2023	NIHR Health Technology Assessment programme	A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial
2023	National Institute for Health and Care Excellence (NICE)	Risankizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 888
2023	National Institute for Health and Care Excellence (NICE)	Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. NICE interventional procedures guidance 773
2023	National Institute for Health and Care Excellence (NICE)	Devices for remote monitoring of Parkinson's disease. NICE diagnostics guidance 51
2023	WorkSafeBC	Cryoneurolysis for shoulder pain
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of domiciliary invasive ventilation for adults with spinal cord injuries
2023	NIHR Health Services and Delivery Research programme	Eye donation from palliative and hospice care contexts: the EDiPPPP mixed-methods study
2023	National Institute for Health and Care Excellence (NICE)	Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 889
2023	National Institute for Health and Care Excellence (NICE)	Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. NICE interventional procedures guidance 772
2023	National Institute for Health and Care Excellence (NICE)	Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. NICE diagnostics guidance 56
2023	National Institute for Health and Care Excellence (NICE)	Difelikefalin for treating pruritus in people having haemodialysis. NICE technology appraisal guidance 890
2023	National Institute for Health and Care Excellence (NICE)	Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 770
2023	National Institute for Health and Care Excellence (NICE)	AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images. NICE diagnostics guidance 55
2023	NIHR Health Technology Assessment programme	Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023	National Institute for Health and Care Excellence (NICE)	Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 891
2023	National Institute for Health and Care Excellence (NICE)	Cryotherapy for chronic rhinitis. NICE interventional procedures guidance 771
2023	National Institute for Health and Care Excellence (NICE)	FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. NICE diagnostics guidance 48
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Embolization vs. conservative management for spontaneous abdominal or pelvic hemorrhage
2023	National Institute for Health and Care Excellence (NICE)	Mosunetuzumab for treating relapsed or refractory follicular lymphoma. NICE technology appraisal guidance 892
2023	National Institute for Health and Care Excellence (NICE)	Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease. NICE interventional procedures guidance 769
2023	National Institute for Health and Care Excellence (NICE)	Transperineal biopsy for diagnosing prostate cancer. NICE diagnostics guidance 54
2023	NIHR Health Services and Delivery Research programme	The effectiveness of sexual assault referral centres with regard to mental health and substance use: a national mixed-methods study – the MiMoS Study
2023	National Institute for Health and Care Excellence (NICE)	Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over. NICE technology appraisal guidance 893
2023	National Institute for Health and Care Excellence (NICE)	Irreversible electroporation for treating prostate cancer. NICE interventional procedures guidance 768
2023	National Institute for Health and Care Excellence (NICE)	Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers. NICE diagnostics guidance 52
2023	National Institute for Health and Care Excellence (NICE)	Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma. NICE technology appraisal guidance 894
2023	National Institute for Health and Care Excellence (NICE)	Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. NICE interventional procedures guidance 766
2023	National Institute for Health and Care Excellence (NICE)	MRI fusion biopsy systems for diagnosing prostate cancer. NICE diagnostics guidance 53
2023	National Institute for Health and Care Excellence (NICE)	Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy. NICE technology appraisal guidance 895
2023	National Institute for Health and Care Excellence (NICE)	Radiofrequency denervation for osteoarthritic knee pain. NICE interventional procedures guidance 767
2023	National Institute for Health and Care Excellence (NICE)	MRI-based technologies for assessing non-alcoholic fatty liver disease. NICE diagnostics guidance 50
2023	National Institute for Health and Care Excellence (NICE)	Bulevirtide for treating chronic hepatitis D. NICE technology appraisal guidance 896
2023	National Institute for Health and Care Excellence (NICE)	Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option. NICE interventional procedures guidance 764
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Non-sterile glove use
2023	National Institute for Health and Care Excellence (NICE)	Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 897
2023	National Institute for Health and Care Excellence (NICE)	Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people. NICE interventional procedures guidance 765
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Somatropin for short stature
2023	National Institute for Health and Care Excellence (NICE)	Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 898
2023	National Institute for Health and Care Excellence (NICE)	Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer. NICE interventional procedures guidance 763
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Direct-acting antivirals for pediatric chronic hepatitis C virus infection